Nintedanib (Ofev, Boehringer Ingelheim) is now the first therapy approved for patients with interstitial lung disease associated with systemic sclerosis.
— Read on www.specialtypharmacytimes.com/
Another soft gel dosage (SGC) form product.
Nintedanib (Ofev, Boehringer Ingelheim) is now the first therapy approved for patients with interstitial lung disease associated with systemic sclerosis.
— Read on www.specialtypharmacytimes.com/
Another soft gel dosage (SGC) form product.